| Year |
Citation |
Score |
| 2015 |
Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World Journal of Clinical Oncology. 6: 299-311. PMID 26677444 DOI: 10.5306/Wjco.V6.I6.299 |
0.318 |
|
| 2015 |
Desai SR, Dietze EC, Skaar D, Jirtle RL, Seewaldt VL. Abstract PR11: Loss of imprinting: Tying prenatal diet to the aggressive biology of triple-negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. 24. DOI: 10.1158/1538-7755.Disp14-Pr11 |
0.354 |
|
| 2014 |
McCray AN, Desai S, Acevedo-Duncan M. The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells. Neurochemical Research. 39: 1691-701. PMID 24965532 DOI: 10.1007/S11064-014-1361-8 |
0.719 |
|
| 2014 |
Desai S, Skaar D, Dietze E, Ambrose A, Jirtle R, Seewaldt V. Abstract C65: Loss of imprinting of KCNK9 in African American women with triple-negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-C65 |
0.34 |
|
| 2014 |
Seewaldt V, Skaar D, Dietze E, Desai S, Jirtle R. Abstract 28: Chemoprevention strategies to target abnormal imprinting in high-risk African American women who do or do not carry a BRCA1 mutation Cancer Research. 74: 28-28. DOI: 10.1158/1538-7445.Cansusc14-28 |
0.332 |
|
| 2013 |
McCray AN, Desai S, Acevedo-Duncan M. Abstract 2952: The PKC-iota inhibitor ICA-1 combined with TRAIL for glioblastoma therapy. Cancer Research. 73: 2952-2952. DOI: 10.1158/1538-7445.Am2013-2952 |
0.69 |
|
| 2012 |
Desai SR, Pillai PP, Patel RS, McCray AN, Win-Piazza HY, Acevedo-Duncan ME. Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma. Carcinogenesis. 33: 10-9. PMID 22021906 DOI: 10.1093/Carcin/Bgr231 |
0.789 |
|
| 2012 |
Desai S, Patel R, McCray AN, Pillai P, Acevedo-Duncan M. Abstract 3760: A novel PKC-iota inhibitor, ICA-1 abrogates cell proliferation in breast cancer Cancer Research. 72: 3760-3760. DOI: 10.1158/1538-7445.Am2012-3760 |
0.744 |
|
| 2011 |
Desai S, Pillai P, Win-Piazza H, Acevedo-Duncan M. PKC-3 promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway Biochimica Et Biophysica Acta - Molecular Cell Research. 1813: 1190-1197. PMID 21419810 DOI: 10.1016/J.Bbamcr.2011.03.007 |
0.788 |
|
| 2011 |
Pillai P, Desai S, Patel R, Sajan M, Farese R, Ostrov D, Acevedo-Duncan M. A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. The International Journal of Biochemistry & Cell Biology. 43: 784-94. PMID 21315177 DOI: 10.1016/J.Biocel.2011.02.002 |
0.797 |
|
| 2011 |
Desai S, Acevedo-Duncan M. Abstract 7: PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphotidylinositol 3-kinase pathway Cancer Research. 71: 7-7. DOI: 10.1158/1538-7445.Am2011-7 |
0.794 |
|
| 2011 |
Desai S, Acevedo-Duncan M. Abstract 2974: Regulation of cyclin dependent kinase 7 through a phosphotidylinositol 3-kinase/PKC-ι mediated cell proliferation cascade Cancer Research. 71: 2974-2974. DOI: 10.1158/1538-7445.Am2011-2974 |
0.788 |
|
| 2011 |
Pillai P, Desai S, Patel R, Sajan M, Farese R, Ostrov D, Acevedo-Duncan M. Erratum to “A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma” [Int. J. Biochem. Cell Biol. 43 (5) (2011) 784–794] The International Journal of Biochemistry & Cell Biology. 43: 1412. DOI: 10.1016/J.Biocel.2011.05.015 |
0.76 |
|
| 2010 |
Desai S, Acevedo-Duncan M. Abstract LB-113: PKC-iota induces uncontrolled glioblastoma cell survival by modulating proapoptotic function of Bad Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-113 |
0.785 |
|
| Show low-probability matches. |